Navigation Links
MIT study suggests caution on new anti-obesity drug in kids
Date:5/7/2008

Anti-obesity drugs that work by blocking brain molecules similar to those in marijuana could also interfere with neural development in young children, according to a new study from MITs Picower Institute for Learning and Memory.

Marijuana is known to be an appetite stimulant, and a new class of anti-obesity drugssuch as rimonabant (trade name Acomplia) developed by Sanofi-Aventis and awaiting approval for use in the United Stateswork by blocking brain receptors that bind to marijuana and other cannabinoids.

Marijuana, derived from the plant Cannabis sativa, contains special active compounds that are referred to collectively as cannabinoids. But other cannabinoids (endocannabinoids) are generated naturally inside the body.

The MIT study, which was done in mice, found that blocking cannabinoid receptors could also suppress the adaptive rewiring of the brain necessary for neural development in children. The work is reported in the May 8 issue of Neuron.

Our finding of a profound disruption of cortical plasticity in juvenile mice suggests caution is advised in the use of such compounds in children, wrote lead author Mark F. Bear, director of the Picower Institute and Picower Professor of Neuroscience.

The researchers investigated plasticitythe brains ability to change in response to experienceby temporarily depriving newborn mice of vision in one eye soon after birth. This well-known experiment induces a long-lasting loss of synapses that causes blindness in the covered eye, while synapses shift to the uncovered eye. How and where this synaptic shift occurs in the primary visual cortex has remained controversial.

Understanding the mechanism behind this phenomenon is key because the same brain mechanisms are used for normal development and may go awry in conditions that cause developmental delays in humans, and may reappear in old age and contribute to synaptic loss during Alzheimer's disease, Bear said.

In mice, the MIT researchers found, even one day of deprivation from one eye starts the shift to dominance of the uncovered eye. But injecting the mice with a cannabinoid receptor blocker halted the shift in certain brain regions, indicating that cannabinoids play a key role in early synaptic development.

Blocking cannabinoids receptors could thwart this developmental process, the researchers said.


'/>"/>

Contact: Teresa Herbert
therbert@mit.edu
617-258-5403
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
2. Study in mice suggests molecules in plants have beneficial effect on Alzheimers disease
3. Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately
4. Weill Cornell receives funding to study creation of new elder abuse center
5. Pilot study reinforces use of portable anteroom HEPA filtration
6. Warning: New Skin Cancer Study Finds Outdoor Workers are Less Likely to Get Screened for Skin Cancer
7. Study shows physician judgement important in reducing RSV-related hospitalizations
8. Study Suggests Stronger Tobacco Control Policies in States With High Smoking Rates Would be Effective in Reducing Smoking and Saving Thousands of Lives
9. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
10. SDSU Study Reveals Eating at Friends and Familys Puts Kids at Higher Risk for Obesity
11. Study shows gene variations may predict risk of breast cancer in women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , ... July 20, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is teaming up with a Microsoft Corp. ... event kicks off on July 24th. , “Team Type 1’s mission overlaps seamlessly ...
(Date:7/20/2017)... ... , ... The Dermatology Clinic announced today the addition of Dr. Scott W. ... LSU, graduating summa cum laude. He attended Emory University School of Medicine in Atlanta ... Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship to ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch to an alternate ... - adjustment (COLA) is a bad deal for older and disabled Americans, says ... would grow even more slowly than the conventional one that is currently used to ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health ... business unit of Constellation Inc., a move that will help the company better serve ... St. Louis, the acquisition is expected to help MTS expand its presence ...
(Date:7/20/2017)... ... 2017 , ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the ... drama teacher who was a summa cum laude graduate of Gardner Webb University. She ... award. After her retirement from public school, Lynn continued to pursue her love for ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
Breaking Medicine Technology: